Molecular pathobiology and immunology of malignant mesothelioma

Journal of Pathology

Volumn 178, Issue 4, 1996, Pages 369-378

  Bielefeldt Ohmann, H ^a   Jarnicki, A G ^b   Fitzpatrick, D R ^c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL TISSUE; CANCER IMMUNOLOGY; HUMAN; HUMAN TISSUE; MESOTHELIOMA; MOUSE; NONHUMAN; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MESOTHELIOMA; PARANEOPLASTIC SYNDROMES;

EID: 0029978180     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199604)178:4<369::AID-PATH460>3.0.CO;2-8     Document Type: Review

References (76)

1. Pelnai PV. Further evidence of non-asbestos-related mesothelioma Scand J Work Environ Health 1988; 14: 141-144
2. Saebø A, Elgjo K, Lassen J Could development of malignant mesothelioma by induced by Yersinta enterocolitica infection? Med Hypoth 1993; 40: 275-277
3. Cicala C, Pompetti F, Carbone M SV40 induces mesotheliomas in hamsters Am J Pathol 1993; 142: 1524-1533
4. Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma, a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol 1992; 9: 124-140.
5. Fitzpatrick DR, Manning LS, Musk AW, Robinson BWS, Bielefeldt-Ohmann H. Potential for cytokine therapy of malignant mesothelioma Cancer Treatment Rev. 1995, 21: 273-288.
6. Gerwin BI. Mesothelial carcinogenesis. Possible avenues of growth factor promotion. In: Jauraud MC, Bignon J, eds The Mesothelial Cell and Mesothelioma. New York. Marcel Dekker, 1994, 223-243
7. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995; 12: 435-460.
8. Jaurand MC, Barrett JC Neoplastic transformation of mesothelial cells. In: Jaurand MC, Bignot J, eds. The Mesothelial Cell and Mesothelioma. New York: Marcel Dekker, 1994; 207-223.
9. Bielefeldt-Ohmann H, Marzo A, Fitzpatrick DR, et al. Immunobiology of murine malignant mesothelioma (MM): characterisation of tumour infiltrating leukocytes and cytokine production in a murine model of MM. Cancer Immunol Immunother 1994; 39: 347-359
10. Walker C, Everitt J, Barrett JC. Possible cellular and molecular mechanisms for asbestos carcinogenicity. Am J Ind Med 1992, 21: 253-273
11. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-5551
12. Heintz NH, Janssen YM, Mossman BT Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci USA 1993, 90: 3299-3303
13. Grabrielson EW, Van der Meeren A, Reddel RR, Reddel H, Gerwin BI, Harris CC. Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity a possible mechanism for tumor promotion by asbestos. Carcinogenesis 1992; 13: 1359-1363
14. Resnick D, Freedman NJ, Xu S, Krieger M. Secreted extracellular domains of macrophage scavenger receptors from elongated trimers which specifically bind crocidolite asbestos J Biol Chem 1993; 268: 3538-3545.
15. Noble PW, Henson PM, Riches DW. Insulin-like growth factor-1 (IGF-1) mRNA expression in bone marrow derived macrophages is stimulated by chrysotile asbestos and bleomycin. A potential marker for a reparative macrophage phenotype. Chest 1991; 99: 79S-80S.
16. Bonner JC, Brody AR. Asbestos-induced alveolar injury Evidence for macrophage-derived PDGF as a mediator of the fibrogenic response. Chest 1991; 99: 54S-55S.
17. Davis JMG, Addison J, Bolton RE, Donaldson K, Jones AD, Smith T The pathogenicity of long versus short fibre samples of amosite asbestos administered to rats by inhalation and intraperitoneal injection. Br J Exp Pathol 1986; 67: 415-430
18. Moalli PA, MacDonald JL, Goodglick LA, Kane AB. Acute injury and regeneration of the mesothelium in response to asbestos fibers Am J Pathol 1987; 128: 426-445.
19. Monchaux G, Bignon J, Jaurand MC, et al. Mesotheliomas in rats following inoculation with acid-leached chrysotile asbestos and other mineral fibers. Carcinogenesis 1991; 2: 229-236
20. Branchaud RM, MacDonald JL, Kane AB. Induction of angiogenesis by intraperitoneal injections of asbestos fibers. FASEB J 1989; 3: 1747-1752.
21. Begin R, Rola-Pleszezynski M, Masse S, et al Asbestos-induced lung injury in the sheep model, the initial alveolitis Environ Res 1983; 30: 195-210
22. Nathan C, Sporn M. Cytokines in context J Cell Biol 1991; 113: 981-986.
23. Robinson BWS, Musk AW Benign asbestos pleural effusion diagnosis and course. Thorax 1981; 36: 896-900.
24. Hillerdal G. Pleural plaques and risk for bronchial carcinoma and mesothelioma A prospective study. Chest 1994; 105: 144-150
25. Browne K. Asbestos related malignancy and the Cairns hypothesis. Br J Ind Med 1991, 48: 73-76.
26. Soosay GN, Griffiths M, Papadaki L, Happerfield L, Borrow L. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation J Pathol 1991; 163: 299-305.
27. Henderson DW, Shilkin KB, Whitaker D, et al. The pathology of malignant mesothelioma, including immunohistology and infrastructure. In: Henderson DW, Shilkin KB, Langois SL, Whitaker D, eds Malignant Mesothelioma. New York: Hemisphere, 1992; 69-139.
28. Davis JMG Histogenesis and fine structure of peritoneal tumors in animals by injections of asbestos. J Natl Cancer Inst 52: 1823-1837
29. Davis JMG The histopathology and ultrastructure of pleural mesotheliomas produced in the rat by injections of crocidolite asbestos. Br J Exp Pathol 1979; 60: 642-652
30. Bielefeldt-Ohmann H, Marzo AL, Himbech RP, Jarnicki AG, Robinson BWS, Fitzpatrick DR Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon-α immunotherapy Cancer Immunol Immunother 1995; 40: 241-250
31. Roggli VL, Sanfilippo F, Shelburne JD. Mesothelioma In: Roggli VL, Greenberg SD, Pratt PC, eds. Pathology of Asbestos-Associated Diseases. Boston: Little, Brown & Co, 1992; 109-164.
32. Symington FW, Symington BE, Liu PY, Viguet H, Santhanam U, Sehgal PB. The relationship of serum IL-6 levels to acute graft-versus-host and hepatorenal disease after human bone marrow transplantation. Transplantation 1992; 54: 457-462.
33. Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982; 61: 1007-1009
34. Wahl SM, Hunt DA, Wakefield LM, et al Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84: 5788-5792.
35. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 1988; 157: 793-800.
36. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumour-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994; 11: 29-44.
37. Higashihara M, Sunaga S, Tange T, Oohashi H, Kurokawa K. Increased secretion of interleukm-6 in malignant mesothelioma cells from a patient with marked thrombocytosis. Cancer 1992; 70: 2105-2108
38. Motoyama T, Honma T, Watanabe H, Honma S, Kumanishi T, Abe S. Interleukin-6-producing malignant mesothelioma. Virchows Arch B [Cell Pathol] 1993; 64: 367-372.
39. Monti G, Jaurand MC, Monnet I, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by γ-interferon treatment. Cancer Res 1994; 54: 4419-4423
40. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-1684.
41. Oliff A. The role of tumor necrosis factor (cachectin) in cachexia. Cell 1988; 54: 141-143.
42. Wronski M, Burt M. Cerebral metastases in pleural mesothelioma, case report and review of the literature. J Neuro-Oncol 1993; 17: 21-26.
43. Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors, key players in growth, differentiation, migration and tumor progression. Curr Opinion Cell Biol 1994; 6: 726-733
44. Asplund T, Versnel MA, Laurent TC, Heldin P. Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts Cancer Res 1993; 53: 388-392
45. Asplund T, Heldin P. Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells Cancer Res 1994; 54: 4516-4523.
46. Hardwick C, Hoare K, Owens R, et al. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J Cell Biol 1992; 117: 1343-1350.
47. Samuel SK, Hurta RAR, Spearman MA, Wright JA, Turley EA, Greenberg AH. TGF-β1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. J Cell Biol 1993; 123: 749-758
48. Stamenkovic I, Aruffo A, Amiot A, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells EMBO J 1991; 10: 343-348.
49. Dougherty GJ, Lansdorp PM, Cooper DL, Humphries RK. Molecular cloning of CD44R1 and CD44R2, two isoforms of the human CD44 lymphocyte 'homing' receptor expressed by hemopoietic cells. J Exp Med 1991; 174: 1-5.
50. Vose BM, Moore M. Human tumour-infiltrating lymphocytes Semin Hematol 1985, 22: 27-40.
51. Henderson DW, Shilkin KB, Whitaker D, et al. Unusual histological types and anatomic sites of mesothelioma. In: Henderson DW, Shilkin KB, Langois SL, Whitaker D, eds. Malignant Mesothelioma. New York: Hemisphere, 1992; 140-166.
52. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Musk AW, Robinson BWS. The potential for interferon-α therapy in mesothelioma. assessment in a murine model J Interferon Cytokine Res 1995; 15: 213-223
53. Hoogsteden HC, Versnel MA, Hop W, vander Kwast ThH, Hilvering C. Immunological characterization of leukocytes in pleural fluid in malignant mesothelioma. Eur Respir Rev 1993; 3: 30-32.
54. Guzman J, Bross KJ, Würtemberger G, Costabel U. Immunocytology in malignant pleural mesothelioma. Chest 1989; 95: 590-595.
55. De Pangher Manzini V, Brollo A, Franceschi S, De Matthaeis M, Talamini R, Bianchi C. Prognostic factors of malignant mesothelioma of the pleura Cancer 1993; 72: 410-417.
56. Kubicka U, Olszewski WL, Maldyk J, Wierzbicki Z, Orkiszewska A. Normal human immune peritoneal cells: phenotypic characteristics. Immunobiology 1989; 180: 80-92.
57. Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG. Inflammatory and immune processes in the human lung in health and disease. Evaluation by bronchoalveolar lavage. Am J Pathol 1979; 97: 149-206.
58. Ruscetti FW, Palladino MA Transforming growth factor-beta and the immune system. Prog Growth Factor Res 1991; 3: 159-171.
59. 2. J Immunol 1994; 153: 1674-1686.
60. Manning LS, Rose AH, Bowman RV, Christmas TI, Garlepp MJ, Robinson BWS. Immune function related to asbestos exposure and mesothelioma, and immunotherapy of mesothelioma. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, eds. Malignant Mesothelioma. New York: Hemisphere, 1992; 278-291.
61. Maeda J, Ueki N, Ohkawa T, et al. Transforming growth factor-beta 1 (TGF-β1)- and β2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. Clin Exp Immunol 1994; 98: 319-322.
62. Alercon B, Berkhou B, Breitmeyer J, Terhorst C. Assembly of the human T cell receptor-CD3 complex takes place in the endoplasmic reticulum and involves intermediary complexes between CD3 γ, δ core and single T cell receptor α and β chains. J Biol Chem 1988, 263: 2953-2961.
63. Chetty R, Gatter K. CD3: structure, function, and role of immunostaining in clinical practice. J Pathol 1994; 173: 303-307.
64. Buferne M, Luton F, Letourneur F, et al. Role of CD3δ in surface expression of the TCR-CD3 complex and in activation for killing analyzed with CD3δ-negative cytotoxic T lymphocyte variant. J Immunol 1992; 148: 657-664.
65. Jarnicki AG, Fitzpatrick DR, Marzo A, Robinson B, Bielefeldt-Ohmann H. Surface antigen and cytokine profile of tumour infiltrating lymphocytes (TIL) in malignant mesothelioma. J Leuk Biol 1993; 54 (Suppl): 90
66. Jarnicki A, Fitzpatrick DR, Robinson BWS, Bielefeldt-Ohmann H. In situ characterization of lymphocytes infiltrating murine malignant mesothelioma: changes in the CD3-chain complex and cytokine expression during tumor development. (Submitted.)
67. Farace F, Angevin E, Vanderplancke J, Escudier B, Triebel F. The decreased expression of CD3 ζ chains in cancer patients is not reversed by IL-2 administration. Int J Cancer 1994; 59: 752-755.
68. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53: 5613-5616.
69. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53: 5620-5622.
70. Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795-1797.
71. Weiss A, Imboden J, Hardy K, et al. The role of the T3/antigen receptor complex in T-cell activation. Annu Rev Immunol 1986, 4: 593-619.
72. Lew F, Tsang P, Holland JF, Warner N, Selikoff U, Bekesi JG. High frequency of immune dysfunction in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol 1986; 6: 225-233
73. Manning LS, Davis MR, Bielefeldt-Ohmann H, et al Evaluation of immunogenicity of murine mesothelioma cells by immunization. Eur Respir Rev 1993, 3: 234-237.
74. Christmas TI, Manning LS, Davis MR, Robinson BWS, Garlepp MJ HLA antigen expression and malignant mesothelioma. Am J Respir Cell Mol Biol 1991; 5: 213-220.
75. Bierer BE, Sleckman BP, Ratnofsky SE, Burakoff SJ. The biological roles of CD2, CD4 and CD8 in T-cell activation Annu Rev Immunol 1989; 7: 579-599.
76. Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance J Exp Med 1988; 167: 1811-1824.